Prevention of ophthalmological diseases in children against the background of certain intestinal pathologies

Prevention of ophthalmological diseases in children against the background of certain intestinal pathologies

Автор: Stadnik A.A., Tebueva D.A., Gashimova M.T., Doronina A.E., Batyrova A.E., Zakharov I.I.

Журнал: Cardiometry @cardiometry

Рубрика: Original research

Статья в выпуске: 30, 2024 года.

Бесплатный доступ

The article discusses the areas of work in the field of prevention of ophthalmic diseases in children against the background of certain intestinal pathologies. The authors note the importance of understanding the need to reduce the risk of developing inflammatory bowel diseases (IBD), which not only negatively affect the functioning of the gastrointestinal tract, but also contribute to the development of ophthalmic diseases in children. Experts have determined that exposure to the human microbiome through the use of probiotics and prebiotics can both ef-fectively reduce the level of inflammation of the intestinal tract, and prevent or reduce the degree of development of various ophthalmological diseases. Accordingly, preventive measures related to the use of probiotics and prebiotics will allow special-ists in the field of ophthalmology to increase the effectiveness of specialized therapy for eye diseases by reducing the nega-tive effect of IBD on the child’s body.

Еще

Ophthalmological diseases, prevention, digestive organs, pathologies of non-infectious nature

Короткий адрес: https://sciup.org/148328274

IDR: 148328274   |   DOI: 10.18137/cardiometry.2024.30.85

Список литературы Prevention of ophthalmological diseases in children against the background of certain intestinal pathologies

  • Li D, et al. Gut microbiota-derived inosine from dietary barley leaf supplementation attenuates colitis through PPARγ signaling activation. Microbiome. 2021 Apr 5;9(1):83. doi: 10.1186/s40168-021-01028-7
  • Bertani L. Treatment and management of chronic inflammatory bowel diseases: optimization of current and future therapeutic options. J. Klin. Med. 2022; 11:5267. doi: 10.3390/jcm11185267.
  • Elhag DA, et al. Treatment of inflammatory bowel diseases and prognostic biomarkers of therapeutic response. International J.M. Sci. 2022;23:6966. doi: 10.3390/ijms23136966.
  • Ni J, et al. Gut microbiota and IBD: causal relationship or correlation? Nat. The Reverend Gastroenterologist. Hepatol. 2017;14:573-84. doi: 10.1038/nrgastro.2017.88.
  • Silva J, et al. Campylobacter spp. as a foodborne pathogen: an overview. The front one. Microbiol. 2011;2:200. doi: 10.3389/fmicb.2011.00200.
  • Nambu R, Muise AM. An expanded understanding of monogenic inflammatory bowel diseases. The front one. Pediatrician. 2020;8:618918. doi: 10.3389/fped.2020.618918.
  • Mak VYu, et al. Epidemiology of inflammatory bowel diseases: East meets West. J. Gastroenterol. Hepatol. 2020;35:380-9. doi: 10.1111/jgh.14872.
  • Perler BK, et al. Presentation of symptoms of inflammatory bowel disease: a descriptive analysis of the initial cohort at the community level. BMK Gastroenterol. 2019;19:47 . doi: 10.1186/s12876-019-0963-7.
  • Nobrega VG, et al. The onset of clinical manifestations in patients with inflammatory bowel diseases. Ark. Gastroenterol. 2018;55:290-5. doi: 10.1590/s0004-2803.201800000-73.
  • Olpin JD, et al. Beyond the intestine: extra-intestinal manifestations of inflammatory bowel disease. Radiography. 2017;37:1135-60. doi: 10.1148/rg.2017160121.
  • Kim JM, Cheon JH. Pathogenesis and clinical prospects of extra-intestinal manifestations of inflammatory bowel diseases. Intest. Res. 2020;18:249-64. doi: 10.5217/ir.2019.00128.
  • Ottaviano G, et al. Ocular manifestations of inflammatory bowel diseases in children: a systematic review and meta-analysis. J. Krones. Colitis. 2018;12:870-9. doi: 10.1093/ecco-jcc/jjy029.
  • Pytrus W, Akutko K, Pytrus T, Turno-Kręcicka A. A Review of Ophthalmic Complications in Inflammatory Bowel Diseases. J Clin Med. 2022 Dec 15;11(24):7457. doi: 10.3390/jcm11247457
  • Bertani L. Treatment and Management of Chronic Inflammatory Bowel Diseases: Optimizing Present and Future Therapeutic Choices. J. Clin. Med. 2022;11:5267. doi: 10.3390/jcm11185267
  • M’Koma AE. Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview. Medicina. 2022;58:567. doi: 10.3390/medicina58050567.
  • Elhag DA, et al. Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. Int. J. Mol. Sci. 2022;23:6966. doi: 10.3390/ijms23136966.
  • Younis N, Zarif R, Mahfouz R. Inflammatory bowel disease: Between genetics and microbiota. Mol. Biol. Rep. 2020;47:3053–63. doi: 10.1007/s11033-020-05318-5.
  • Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: Causation or correlation? Nat. Rev. Gastroenterol. Hepatol. 2017;14:573–84. doi: 10.1038/nrgastro.2017.88.
  • Habot-Wilner Z, et al. Demographic and clinical features of pediatric uveitis in Israel. Okul. Immunol. Inflammation. 2018;28:43-53.
  • Ramanan AV, et al. SYCAMORE Research Group; and others. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N. eng. J. Med. 2017;376:1637-46.
  • Parker DM, et al. Chronic anterior uveitis in children: psychosocial problems for patients and their families. I am. J. Ophthalmol. 2018;191:xvi–xxiv.
  • Thorne JE, et al. The risk of developing cataracts in children with juvenile idiopathic uveitis associated with arthritis treated with topical corticosteroids. Ophthalmology. 2020;127:S21–6.
  • Navarrete A, Koryat A, Amer R. The effect of cystic macular edema associated with parsplanitis on visual results and treatment in children. The Grefess Arch. The wedge. Exp. Ophthalmol. 2020;258:1803-11.
  • Jayakumar K, et al Research on early rheumatoid arthritis. Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in a group of patients receiving conventional HDL. Rheumatology. 2012;51:169-75.
  • Javakhir D, Olsen J, Hetland ML. Sex differences in response to therapy with antitumor necrosis factor in early and established rheumatoid arthritis – results from the DANBIO registry. J. Rheumatol. 2012; 39: 46-53.
  • Forslind, K, et al. Sex: the main predictor of remission in early rheumatoid arthritis? Anna. Reum. Dis. 2007;66:46-52.
  • Matysiak A, et al. Characterization of Ocular Surface Microbial Profiles Revealed Discrepancies between Conjunctival and Corneal Microbiota. Pathogens. 2021 Mar 30;10(4):405. doi: 10.3390/pathogens10040405
  • Liang X, et al. Demodex Infection Changes Ocular Surface Microbial Communities, in Which Meibomian Gland Dysfunction May Play a Role. Ophthalmol Ther. 2021 Sep;10(3):601-617. doi: 10.1007/s40123-021-00356-z
  • Loggia, Poon LYC. Systemic paraquat intoxication manifested by peripheral ulcerative keratitis: case description and literature review. Shark Immune Inflammo. 2020; 28(6): 871-875. https://doi.org/10.1080/09273948.2019.1640882
  • Mishra AV, et al. Peripheral ulcerative keratitis secondary to atypical hemolytic-uremic syndrome. The cornea. 2020; 39(11): 1431–1432. https://doi.org/10.1097/ICO.0000000000002317
  • Baim AD, et al. The microbiome and ophthalmic disease. Exp Biol Med (Maywood). 2019 Apr; 244(6): 419-429. doi: 10.1177/1535370218813616.
  • Knight R, et al. The Microbiome and Human Biology. Annu Rev Genomics Hum Genet. 2017 Aug 31; 18: 65-86. doi: 10.1146/annurev-genom-083115-022438.
  • Gilbert JA, Jansson JK, Knight R. The Earth Microbiome project: successes and aspirations. BMC Biol. 2014 Aug 22; 12: 69. doi: 10.1186/s12915-014-0069-1
  • Cavuoto KM, Banerjee S, Galor A. Relationship between the microbiome and ocular health. Ocul Surf. 2019 Jul; 17(3): 384-392. doi: 10.1016/j.jtos.2019.05.006.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp